MarinaKremyanskayaMD

Oncology • New York, NY

Hematologic Oncology

Assistant Professor, Medicine, Icahn School of Medicine at Mount Sinai

Join to view full profile

Dr. Kremyanskaya is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kremyanskaya's full profile

Already have an account?

Office
10 E 102nd St
New York, NY 10029
Phone+1 212-241-6756

Fax+1 212-731-5210

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2009 - 2012
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2006 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2006

Certifications & Licensure

NY State Medical License 2008 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Start of enrollment: 2013 Jan 01
Completed
Phase 1, Phase 2
Ruxolitinib in Combination With Autotransplant Start of enrollment: 2015 May 01
Withdrawn
Not Applicable
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2020 Jun 12
Terminated
Phase 1
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Start of enrollment: 2023 Apr 04
Recruiting
Phase 1
Roles: Contact, Principal Investigator, Sponsor-Investigator
Study to Assess SLN124 in Patients With Polycythemia Vera Start of enrollment: 2023 Jan 26
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML Start of enrollment: 2023 Jul 18
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Diagnosis and Treatment of Polycythemia Vera: A Review.
Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Ronald Hoffman
JAMA. 2025-01-14
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.
Douglas Tremblay, Clifford Csizmar, Courtney D DiNardo, Somedeb Ball, Noa Rippel
Leukemia. 2025-01-01
4 citations
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos
The Lancet. Oncology. 2024-10-01

Lectures

A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021May 12th, 2021
Hepcidin Mimetic Eliminates Need for Phlebotomy in Polycythemia VeraDecember 18th, 2020
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual MeetingNovember 4th, 2020
Join now to see all